StonvexLoadingβ¦
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest newsβ¦
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview Β· 3 reports / hour Β· No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro βNext report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals β Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Ξ | Vol |
|---|---|---|---|---|
| 05-13 | $17.00 | $18.72 | +10.12% | 0.4M |
| 05-14 | $18.76 | $20.50 | +9.28% | 0.4M |
| 05-15 | $20.20 | $19.61 | -2.92% | 0.3M |
| 05-18 | $19.49 | $19.88 | +2.00% | 0.3M |
| 05-19 | $19.49 | $19.90 | +2.10% | 0.2M |
Indicator values from Polygon. Educational only β single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website β Stonvex does not proxy or store filings.
No sell-side coverage available for FTK.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for FTK.
No fundamental metrics available yet for this ticker β common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $70.05M | $237.26M | $169.74M | $113.71M |
Operating Income | $7.59M | $23.24M | $17.26M | $8.15M |
Net Income | $4.66M | $30.53M | $27.50M | $7.15M |
EPS (Diluted) | $0.12 | $0.84 | $0.78 | $0.21 |
Total Assets | $231.84M | $220.05M | $212.69M | $172.24M |
Total Liabilities | $113.67M | $106.99M | $102.19M | $100.39M |
Cash & Equivalents | $5.68M | $5.73M | $4.60M | $5.03M |
Free Cash Flow OCF β CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 36.17M | 30.13M | 29.99M | 29.85M |
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
FTK is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1137-name primary list.
DNA analysis is not available for this ticker.